Onyx Seeks Suitors After Rejecting Amgen’s Bid

July 1 (Bloomberg) -- Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Onyx shares surged. Dominic Chu reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)

Are Cloud Robotics Are a Game-Changer?
27:21 - “The Industries of the Future” Author Alec Ross discusses cloud robotics and the future of robot technology on “Bloomberg West.” (Source: Bloomberg)
  • Is There a Tech Talent Shortage in Silicon Valley?
  • Blackberry Cuts Jobs in Push to Profit
  • Bloomberg Businessweek: The Female Solidarity